Arvinas, Inc. Q4 FY2025 earnings call

Randy Thiel discussed 2025 as a transformative year with progress across the pipeline, including submitting a New Drug Application, redefining strategy, and having four ongoing clinical trials. Noah Berkowitz talked about ARV-102, ARV-806, ARV-393, and ARV-027. Angela Cacace shared details on ARV-027, ARV-6723, and the oral pan-KRAS PROTAC program. Andrew Saik reviewed financial highlights, including cash position, expenses, and stock repurchase program.

In the fourth quarter of 2025, revenue was $9.5 million compared to $59.2 million in the same period of 2024. The decrease was primarily due to a decrease of $40.3 million from the Novartis license agreement. For the full year 2025, revenue was $262.6 million compared to $263.4 million in 2024. General and administrative expenses in the fourth quarter were $23 million vs. $34.1 million in 2024, and for the year were $95.9 million vs. $165.4 million. Research and development expenses in the fourth quarter were $61.1 million vs. $83.3 million in 2024, and for the year were $285.2 million vs. $348.2 million.

Maintaining cash runway guidance into 2028, anticipating sharing new clinical data from Phase 1 trials of ARV-102, ARV-806, and ARV-393 in 2026, with ARV-027 entering human trials and ARV-6723 planning first-in-human studies later in the year.

Includes various questions from analysts about the pipeline, data expectations, safety, partnerships, and more, with responses from company executives addressing topics like differentiation of programs, data readouts, safety in studies, and partnership progress